mevrometostat
Sponsor Pfizer INC · listed as PFE
mevrometostat is a drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 2, 2026 (day precision, medium confidence), tied to trial NCT06629779. That trial is in Phase 3 and currently recruiting, studying Metastatic Castration-Resistant Prostate Cancer. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for mevrometostat
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-02 | READOUT | medium | NCT06629779 |
| 2026-12-28 | READOUT | medium | NCT06551324 |
Trials for mevrometostat in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06629779 catalyst | Phase 3 | Recruiting | 2026-12-02 | Experimental | Pfizer | Metastatic Castration-Resistant Prostate Cancer |
| NCT06551324 catalyst | Phase 3 | Active, not recruiting | 2026-12-28 | Experimental | Pfizer | Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
| NCT07028853 | Phase 3 | Recruiting | 2028-09-12 | Experimental | Pfizer | Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer… |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More PFE catalysts